Vasopressin Receptor Antagonist - Pipeline Insight Report 2018 Featuring Astellas, Bayer, Biovie, Azevan Pharmaceuticals, Ferring & Roche - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Vasopressin Receptor Antagonist - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Vasopressin Receptor Antagonist - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vasopressin Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Vasopressin Receptor Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the report:Provides a snapshot of the therapeutics pipeline activity for Vasopressin Receptor Antagonist Features the Vasopressin Receptor Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Vasopressin Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Vasopressin Receptor Antagonist
Key Topics Covered:
1. Report Introduction
2. Vasopressin Receptor Antagonist - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Vasopressin Receptor Antagonist
4. Comparative Analysis
5. Vasopressin Receptor Antagonist Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Vasopressin Receptor Antagonist Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies MentionedAstellas Bayer Biovie Azevan Pharmaceuticals Ferring Roche
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rx8rpx/vasopressin?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005404/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/30/2018 12:46 PM/DISC: 11/30/2018 12:46 PM